Recent News

• 12.11.2025 - Plus Therapeutics Expands CNSide Assay Platform to State of California
• 12.09.2025 - Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
• 12.09.2025 - December 9, 2025 - December 12, 2025 : San Antonio Breast Cancer Symposium
• 12.09.2025 - December 9, 2025 - December 12, 2025 : San Antonio Breast Cancer Symposium
• 12.04.2025 - Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting
• 12.01.2025 - Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium
• 11.24.2025 - Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases
• 11.20.2025 - Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
• 11.19.2025 - November 19, 2025 - November 23, 2025 : Society for Neuro-Oncology (SNO) Annual Meeting
• 11.19.2025 - November 19, 2025 - November 23, 2025 : Society for Neuro-Oncology (SNO) Annual Meeting

Recent Filings

• 11.17.2025 - EX-99.1 EX-99.1
• 11.17.2025 - 8-K Current report
• 11.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.30.2025 - 8-K Current report
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - EX-99.1 EX-99.1